RNAsum: A tool for personalised genome and transcriptome interpretation for improved cancer diagnostics
Kanwal, S.; Marzec, J.; Vissers, J. H. A.; Diakumis, P.; Varghese, L.; Tork, L.; Hofmann, O.; Grimmond, S.; Luen, S. J.
Show abstract
BackgroundThe integration of whole-genome sequencing (WGS) and whole-transcriptome sequencing (WTS) has revolutionized cancer diagnostics by enabling comprehensive molecular profiling of tumours. WGS uncovers genomic alterations such as single nucleotide variants, structural variants, and copy number changes, whereas WTS reveals their functional consequences through expression profiles and fusion detection. Together, these technologies offer unparalleled potential to guide precision oncology by identifying actionable biomarkers and stratifying patients for targeted therapies or clinical trials. Recent studies have shown that nearly half of patients experience improved clinical outcomes when treatment is guided by combined WGTS analysis. However, automated and effective integration and visualisation of these complex data remain the major challenges for personalized cancer sample interpretation. ResultsWe developed RNAsum, an open-source tool for integrating and interpreting whole-genome sequencing (WGS) and whole-transcriptome sequencing (WTS) data from individual cancer patient samples. RNAsum compares patient data to The Cancer Genome Atlas (TCGA) cohorts, integrating quantitative expression data with genomic findings to validate and prioritise clinically relevant alterations and enhance diagnostic accuracy. Clinical applicability evaluation performed across 60 patients demonstrated that 68% (140/205) of the clinically reportable variants identified by WGS, spanning copy number changes, truncating mutations and gene fusions, were supported at the RNA level as detected by WTS and reported by RNAsum. Case studies further highlight the ability of RNAsum to confirm clinically reportable variants, refine diagnoses, and identify novel therapeutic targets, particularly in complex cases involving multiple genomic alterations and drug resistance mechanisms. ConclusionRNAsum effectively bridges the gap between genome and transcriptome analyses, significantly advancing the integration of multiomics data in personalized cancer care. Its ability to validate clinically reportable variants at the RNA level and elucidate complex alterations, including those driving drug resistance, highlights RNAsums potential to improve molecular tumour profiling and support clinical decision-making. Freely available as an R package on GitHub at https://github.com/umccr/RNAsum, RNAsum provides an accessible and scalable solution for researchers and clinicians, representing a significant step towards the routine application of integrated genomic and transcriptomic analyses in precision oncology.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
Similar papers in this journal
- Use of high-plex data reveals novel insights into the tumour microenvironment of clear cell renal cell carcinoma 93%
- Development of a Single Molecule Counting Assay to Differentiate Chromophobe Renal Cancer and Oncocytoma in Clinics 93%
- Genomic profile in TGCT Mexican patients reveals a potential biomarker of sensitivity to platinum-based therapy 92%
Similar papers in this journal
- Specifications of the ACMG/AMP variant interpretation guidelines for germline TP53 variants 93%
- Cancer SIGVAR: A semi-automated interpretation tool for germline variants of hereditary cancer-related genes 92%
- Phasing of de novo mutations using a scaled-up multiple amplicon long-read sequencing approach 91%
Similar papers in this journal
- Analysis of Mutational Profile of Hypopharyngeal and Laryngeal Head and Neck Cancers Identifies KMT2C as a Potential Tumor Suppressor 94%
- Circulating tumor fraction analyses with ultra-low pass whole genome sequencing predict response to chemoradiation and recurrence in stage IV small cell carcinoma of the cervix: a longitudinal case study 92%
- A structure-based tool to interpret the significance of kinase mutations in clinical next generation sequencing in cancer 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.